ProQR Therapeutics Price Target Announced at $5.00/Share by Evercore ISI Group
Evercore Initiates ProQR Therapeutics(PRQR.US) With Buy Rating, Announces Target Price $5
ProQR Therapeutics Assumed With an Overweight at Cantor Fitzgerald
ProQR Therapeutics Names Hom as CFO, Lopez Lopez as Chief Medical Officer
ProQR Strengthens Leadership With Appointments of CFO and CMO to Support Next Phase of Growth
ProQR Therapeutics Announces Appointment of Dennis Hom as Chief Financial Officer >PRQR
Express News | ProQR Strengthens Leadership With Appointments of CFO and Cmo to Support Next Phase of Growth
Risks Still Elevated At These Prices As ProQR Therapeutics N.V. (NASDAQ:PRQR) Shares Dive 30%
ProQR Therapeutics Price Target Maintained With a $4.00/Share by Chardan Capital
ProQR Therapeutics Is Maintained at Buy by Chardan Capital
HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $12
Express News | ProQR Therapeutics NV Files for Shelf of up to up to 3.5 Mln Ordinary Shares by Selling Stockholder - SEC Filing
ProQR Therapeutics Reports FY24 EPS (EUR 0.32) Vs (EUR 0.35) Last Year
ProQR Therapeutics | 20-F: FY2024 Annual Report
ProQR Therapeutics Advances Axiomer RNA Editing Pipeline With Key Milestones Set for 2025
Express News | ProQR Therapeutics NV: EUR 149.4 Mln Cash and Cash Equivalents as of End of 2024, Providing Runway Into Mid-2027
ProQR Announces Year End 2024 Operating and Financial Results
ProQR Therapeutics FY24 Loss EUR27.8M >PRQR
Citi Upgrades ProQR Therapeutics(PRQR.US) to Buy Rating, Raises Target Price to $4
ProQR Therapeutics Upgraded to Buy From Neutral at Citi